NCT06907485 - A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 31, 2027

Conditions

Pediatric Brain Tumor

Interventions

DRUG

Aminolevulinic acid hydrochloride

Pediatric patients diagnosed with a new or recurrent brain tumor, suspected to be either a high-grade or low-grade glioma, and scheduled for surgical removal will receive aminolevulinic acid hydrochloride prior to surgery for resection of the brain tumor.

Trial Locations (2)

15224

UPMC Children's Hospital of Pittsburgh, Pittsburgh

60068

MidWest Children's Brain Tumor Center, Advocate Children's Hospital Park Ridge, Chicago